Tamoxifen for disease-negative but MCA-positive breast cancer patients

Oncology Reports

Volumn 4, Issue 4, 1997, Pages 843-847

  Merimsky, Ofer ^a,b   Kovner, Felix ^a   Inbar, Moshe ^a   Hareuveni, Mara ^a   Rosenboim, Yariv ^a   Chaitchik, Samario ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Breast cancer; Early treatment; Follow up; MCA; Metastatic disease; tamoxifen; Tumor markers

Indexed keywords

TAMOXIFEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PALLIATIVE THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RELIABILITY; SURVIVAL RATE; TREATMENT PLANNING;

EID: 0030838584     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.4.4.843     Document Type: Article

References (11)

1. Merimsky O, Hareuveni M, Inbar M, Horev J, Keydar I, Kovner F and Chaitchik S: Increasing serum levels of mucin-like carcinoma associated antigen and mucinous antigen H23 in clinically disease free breast cancer patients. Diagn Oncol 3: 61-66, 1993.
2. Merimsky O, Inbar M, Hareuveni M, Witenberg B, Wolman Y and Chaitchik S: Serial serum MCA measurements in the follow-up of breast cancer patients. Eur J Cancer 27: 1440-1444, 1991.
3. Jager W, Kramer S, Palapelas V and Norbert L: Breast cancer and clinical utility of CA 15-3 and CEA. Scand J Clin Lab Invest Suppl 221: 87-92, 1995.
4. Jager W: The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements. Eur J Cancer Prevent 2 (Suppl 3): 133-139, 1993.
5. Kovner F, Merimsky O, Hareuveni M, Wigler N and Chaitchik S: Treatment of disease-negative but marker-positive breast cancer patients by tamoxifen: preliminary results of a prospective controlled randomized trial. Cancer Chemother Pharmacol 35: 80-83, 1994.
6. Cooper EH, Forbes MA, Hancock AK, Price JJ and Parker D: An evaluation of mucin-like carcinoma associated antigen (MCA) in breast cancer. Br J Cancer 59: 797-800, 1989.
7. Mueller-Brand J, Macke H and Hegialjai T: Clinical value of a mucin-like carcinoma-associated antigen (MCA) in the monitoring of breast cancer patients. J Nucl Med 29: 894, 1988.
8. Steger GG, Mader R, Derfler K, Moser K and Dittrich C: Mucin-like cancer-associated antigen (MCA) compared with CA-15.3 in advanced breast cancer. Klin Wochenschr 67: 813-817, 1989.
9. Cavalli F, Beer M and Martz G: Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer. Report of the Swiss group for clinical cancer research. Br J Med 286: 5-8, 1983.
10. Tomiak E and Piccart M: Routine follow-up of patients after primary therapy for early breast cancer: changing concepts and challenges for the future. Ann Oncol 4: 199-204, 1993.
11. Tomin R and Donegan WL: Screening for recurrent breast cancer - its effectiveness and prognostic value. J Clin Oncol 5: 62-67, 1987.